¦rÅé¤j¤¤¤pº©½Í°ü¬ì¸~½F-¤l®c¤º½¤Àù©M§Z±_Àù¥x¤j°ü²£³¡¥DªvÂå®v³¯¦t¥ß(2019/11/08)¤l®c¤º½¤Àù    ¤l®c¤º½¤Àù¬O·½µo¦Û¤l®c¤º½¤ªºÀù¯g¡A¬°¤w¶}µo°ê®a±`¨£°ü¬ìÀù¯g¤§¤@¡A¤l®c¤º½¤Àù³Ì±`¨£ªº²Ó­MÃþ«¬¬°¤l®c¤º½¤¼ËÀù(endometrioidadenocarcinoma)¡A¨ä¥L¸û¨u¨£ªº²Ó­M«¬ºA«h¦³¼ß²Ó­MÀù(serousadenocarcinoma)¥H¤Î«G²Ó­MÀù(clearcelladenocarcinoma)µ¥¡C¦b¥xÆW¡A¤l®c¤º½¤Àù¤w¸g¶W¶V¤l®cÀVÀù¡A¦¨¬°µo¥Í²v³Ì°ªªº¤k©Ê¥Í´Þ¾¹©xÀù¯g¡C¤l®c¤º½¤Àù·s½T¶E¯f¨Ò¼Æ³v¦~¤W¤É¡A®Ú¾Ú½Ã¥ÍºÖ§Q³¡²Î­p¡A¥Á°ê105¦~¬ù¦³¨â¤d¨â¦Ê¦ì·s½T¶Eªº¤l®c¤º½¤Àù¯f±w¡A¬Oªñ¤Q¦~¤º¦¨ªø§Ö³tªºÀù¯g¤§¤@¡C¤l®c¤º½¤Àùªº¹w«á¬Û·í¦n¡A±wªÌ¤­¦~¦s¬¡²v¹F94%¡C    ¤l®c¤º½¤Àù¦nµo©ó50~70·³ªº¤k©Ê¡A¦h¼Æ¬°°±¸g«á°ü¤k¡A¦ýªñ¦~¨Ó¤l®c¤º½¤Àùªº¯f±w¦~ÄÖ¼h¦³³vº¥¦~»´¤ÆªºÁͶաC¿©±w¤l®c¤º½¤Àùªº°ª¦MÀI±Ú¸s¥]§tªÎ­D¡B°ª¦åÀ£¡B¿}§¿¯f¡Bªì¸g¸û¦­¡B°±¸g¸û±ß¡B¨S¦³¥Í¨|¡B¦hÅn©Ê§Z±_¯g­Ô¸s¡B»Û¿E¯À¹L°ª¡B¨ã¦³¤Àªc»Û¿E¯Àªº§Z±_Áû²É²Ó­M½F¥H¤Î¨Ï¥Î¨ÅÀù§Ü²üº¸»XÃĪ«(Tamoxifen)ªº°ü¤k¡C    ¤l®c¤º½¤Àù±wªÌ¥D­n¯gª¬¬°¤£¥¿±`ªº¤l®c¥X¦å¡A¤w°±¸gªº°ü¤k·|¥X²{°±¸g«á¥X¦åªº¯gª¬¡A¦Ü©ó©|¥¼°±¸gªº°ü¤k«h¤j¦h¥D¶D¸g¦å¶q²§±`¼W¦h¡B¤ë¸g¥X¦å´Á¹Lªø©Î«D¸g´Á¤£¥¿±`¥X¦å¡C¤l®c¤º½¤ÀùªºÁ{§É¶EÂ_¥H¤l®c¤º½¤¨í·k¤â³N¨ú±o¤l®c¤º½¤²Õ´¬°¥D­n¶EÂ_¤è¦¡¡C¨ä¥L»²§U©ÊªºÀˬd¥]§t¶W­µªiÀˬd¡B¤l®cÃèµ¥¡C¤l®cÃè°£¤F¯à½T©w¯fÅܦì¸m©M½d³ò¥~¡AÁÙ¯à¦P®É¹ï¥iºÃ¯f¨_¤Á¤ù    ¤â³N¬OªvÀø¤l®c¤º½¤Àù³Ì¥D­nªº¤è¦¡¡A¤â³N¤è¦¡¥]¬A¤Á°£¤l®c¡B¨â°¼§Z±_©M¿é§ZºÞ¥H¤Î°©¬ÖµÄ²O¤Úµ²ºK°£(¦³®É»Ý­n¶i¦æ¥D°Ê¯ß®Ç²O¤Úµ²ºK°£)¡A¦P®É¥ç·|¦¬¶°°©¬ÖµÄ²G¤¤ªº²Ó­M°eÀË¥H½T»{¨ä¤¤¬O§_¦s¦b¦³´c©Ê²Ó­M¡C¸g¥Ñ¤â³N¨ú¤Uªº¼Ð¥»¦b³z¹L¯f²zÀˬd«á¡A¤~¯à°÷½T©w¤l®c¤º½¤Àùªº´Á§O¡C¤l®c¤º½¤Àù¤À´Á²Ä¤@´Á¡G¸~½F«]­­¦b¤l®c¤ºIA´Á¡G¸~½F¨S¦³©Î«Iŧ¤l®c¦Ù¦×¼h¤p©ó¤@¥b¡CIB´Á¡G¸~½F«Iŧ¤l®c¦Ù¦×¼h¤@¥b©Î¤@¥b¥H¤W¡C²Ä¤G´Á¡G¸~½F«Iŧ¤l®cÀV¶¡½è²Õ´¡A¦ý¥¼ÂX´²¨ì¤l®c¥~²Ä¤T´Á¡G¸~½F§½³¡©Î°Ï°ìÂX´²IIIA´Á¡G¸~½F«Iŧ¤l®c¼ß½¤¼h©ÎªþÄݾ¹©x¡CIIIB´Á¡G¸~½F«Iŧ³±¹D©Î¤l®cÀV®Ç²Õ´¡CIIIC´Á¡G¸~½FÂಾ¦Ü°©¬ÖµÄ©Î¥D°Ê¯ß®Ç²O¤Úµ²¡CIIIC1´Á¡G°©¬ÖµÄ²O¤Úµ²Âಾ¡CIIIC2´Á¡G¥D°Ê¯ß®Ç²O¤Úµ²Âಾ¡C²Ä¥|´Á¡G¸~½F«Iŧ»H¯Ö©Î¸z¤lªºÂH½¤¼h¡A©Î»·³B¾¹©xÂಾIVA´Á¡G¸~½F«Iŧ»H¯Ö©Î¸z¤lÂH½¤¼h¡CIVB´Á¡G»·³BÂಾ¥]¬A¸¡µÄ¤ºÂಾ©Î¸¡ªÑ·¾²O¤Úµ²Âಾ¡C    ¤â³N«á¬O§_»Ý­n¦A±µ¨ü»²§U©ÊªvÀø(adjuvanttreatment)µø´_µo­·ÀI°ª§C¦